231 related articles for article (PubMed ID: 30266764)
1. Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Unruh D; Mirkov S; Wray B; Drumm M; Lamano J; Li YD; Haider QF; Javier R; McCortney K; Saratsis A; Scholtens DM; Sarkaria JN; James CD; Horbinski C
Clin Cancer Res; 2019 Jan; 25(2):747-759. PubMed ID: 30266764
[TBL] [Abstract][Full Text] [Related]
2. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
3. Mutant IDH1 and thrombosis in gliomas.
Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
[TBL] [Abstract][Full Text] [Related]
4. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
6. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
Sears TK; Horbinski CM; Woolard KD
J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
[TBL] [Abstract][Full Text] [Related]
7. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors.
Perycz M; Dabrowski MJ; Jardanowska-Kotuniak M; Roura AJ; Gielniewski B; Stepniak K; Dramiński M; Ciechomska IA; Kaminska B; Wojtas B
Acta Neuropathol Commun; 2024 May; 12(1):72. PubMed ID: 38711090
[TBL] [Abstract][Full Text] [Related]
10. Metabolic changes related to the IDH1 mutation in gliomas preserve TCA-cycle activity: An investigation at the protein level.
Dekker LJM; Wu S; Jurriëns C; Mustafa DAN; Grevers F; Burgers PC; Sillevis Smitt PAE; Kros JM; Luider TM
FASEB J; 2020 Mar; 34(3):3646-3657. PubMed ID: 31960518
[TBL] [Abstract][Full Text] [Related]
11. Mutant IDH1 and seizures in patients with glioma.
Chen H; Judkins J; Thomas C; Wu M; Khoury L; Benjamin CG; Pacione D; Golfinos JG; Kumthekar P; Ghamsari F; Chen L; Lein P; Chetkovich DM; Snuderl M; Horbinski C
Neurology; 2017 May; 88(19):1805-1813. PubMed ID: 28404805
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
13. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
[TBL] [Abstract][Full Text] [Related]
14. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.
Gargini R; Segura-Collar B; Herránz B; García-Escudero V; Romero-Bravo A; Núñez FJ; García-Pérez D; Gutiérrez-Guamán J; Ayuso-Sacido A; Seoane J; Pérez-Núñez A; Sepúlveda-Sánchez JM; Hernández-Laín A; Castro MG; García-Escudero R; Ávila J; Sánchez-Gómez P
Sci Transl Med; 2020 Jan; 12(527):. PubMed ID: 31969485
[TBL] [Abstract][Full Text] [Related]
15. Mutant Isocitrate Dehydrogenase 1 Disrupts PKM2-β-Catenin-BRG1 Transcriptional Network-Driven CD47 Expression.
Gowda P; Patrick S; Singh A; Sheikh T; Sen E
Mol Cell Biol; 2018 May; 38(9):. PubMed ID: 29463646
[TBL] [Abstract][Full Text] [Related]
16. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
Unruh D; Zewde M; Buss A; Drumm MR; Tran AN; Scholtens DM; Horbinski C
Sci Rep; 2019 Jun; 9(1):8946. PubMed ID: 31222125
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
[TBL] [Abstract][Full Text] [Related]
18. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
19. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
20. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
Fukunaga T; Fujita Y; Kishima H; Yamashita T
PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
